Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept

Adv Drug Deliv Rev. 2011 Jul 18;63(8):558-67. doi: 10.1016/j.addr.2011.02.003. Epub 2011 Feb 16.

Abstract

Epithelial-mesenchymal transition (EMT) is a fundamental mechanism in development driving body plan formation. EMT describes a transition process wherein polarized epithelial cells lose their characteristics and acquire a mesenchymal phenotype. The apico-basal polarity of epithelial cells is replaced by a front-rear polarity in mesenchymal cells which favor cell-extracellular matrix than intercellular adhesion. These events serve as a prerequisite to the context-dependent migratory and invasive functions of mesenchymal cells. In solid tumors, carcinoma cells undergoing EMT not only invade and metastasize but also exhibit cancer stem cell-like properties, providing resistance to conventional and targeted therapies. In cardiovascular systems, epicardial cells engaged in EMT contribute to myocardial regeneration. Conversely, cardiovascular endothelial cells undergoing EMT cause cardiac fibrosis. Growing evidence has shed light on the potential development of novel therapeutics that target cell movement by applying the EMT concept, and this may provide new therapeutic strategies for the treatment of cancer and heart diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / physiopathology
  • Cell Movement / drug effects
  • Drug Delivery Systems
  • Drug Design
  • Drug Resistance, Neoplasm
  • Epithelial-Mesenchymal Transition*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology